CONCERT PHARMACEUTICALS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation expense
Amortization of premiums on investments
Amortization of discount on loan payable
Amortization of deferred financing costs
Amortization of deferred lease incentive
Non-cash license consideration (Note 12)
Non-cash lease expense
Other non-cash items
Unrealized loss on marketable equity securities
Unrealized loss on warrant liabilities (Note 14)
Loss (gain) on disposal of asset
Loss on extinguishment of debt
Changes in operating assets and liabilities:
Accounts receivable
Contract asset
Interest receivable
Prepaid expenses and other current assets
Restricted cash
Other assets
Accounts payable
Accrued expenses and other liabilities
Income taxes receivable
Income taxes payable
Deferred rent
Deferred revenue

Net cash provided by (used in) operating activities
Operating lease liability
Deferred revenue

Net cash used in operating activities
Investing activities
Purchases of property and equipment
Purchases of investments
Maturities of investments
Net cash (used in) provided by investing activities
Net cash provided by investing activities

Financing activities
Proceeds from loan, net
Repayment of loan
Proceeds from exercise of warrants
Repurchase of common stock pursuant to share surrender
Proceeds from at-the-market offering, net of issuance costs
Proceeds from exercise of stock options
Income tax benefit from exercise of stock options
Payment of public offering costs
Net cash provided by financing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Proceeds from common and preferred stock, warrants and royalty interest sold, net of issuance costs
Net cash provided by financing activities
Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental cash flow information:
Cash paid for income taxes
Cash paid for interest
Purchases of property and equipment unpaid at period end
Tenant improvements paid by landlord (Note 11)
Issuance of stock warrants
Public offering costs unpaid at period end
Cash paid included in measurement of lease liabilities
Warrants issued

Comments